Equities

Impact Biomedical Inc

Impact Biomedical Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.84
  • Today's Change0.205 / 7.80%
  • Shares traded32.99k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 01:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments0.000.000.05
Total Receivables, Net0.330.020.20
Total Inventory------
Prepaid expenses00.100.04
Other current assets, total------
Total current assets0.330.120.29
Property, plant & equipment, net0.290.28--
Goodwill, net252525
Intangibles, net192021
Long term investments00.784.82
Note receivable - long term00.195.08
Other long term assets------
Total assets454656
LIABILITIES
Accounts payable0.830.540.12
Accrued expenses0.230.060.01
Notes payable/short-term debt129.9913
Current portion long-term debt/capital leases------
Other current liabilities, total------
Total current liabilities131113
Total long term debt000
Total debt129.9913
Deferred income tax3.243.243.86
Minority interest3.043.113.32
Other liabilities, total------
Total liabilities191720
SHAREHOLDERS EQUITY
Common stock0.010.070.13
Additional paid-in capital383838
Retained earnings (accumulated deficit)(13)(8.63)(1.57)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity253037
Total liabilities & shareholders' equity454656
Total common shares outstanding121212
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.